CellREDM: the same hADM idea, ground finer
CellREDM belongs to the same class as Re2O. The premise is identical — take donated human skin, strip out the cells, and put the remaining structural material back into a dermis that has lost its own. What differs is particle size, and that difference decides where the product can go. This page covers what it is, how we choose between the two hADM products, and where it stops being the right answer.
In one paragraph
CellREDM is an injectable skin booster made in South Korea by Hans Biomed. Its active material is hADM — human acellular dermal matrix. Donated human skin is processed to remove all cells and DNA, and the remaining extracellular matrix — collagen, elastin, glycosaminoglycans — is milled to roughly 75-micrometre particles and injected into the dermis. It replaces material the skin has lost rather than signalling the skin to make more.
At a glance
| Category | Injectable skin booster (human tissue–derived) |
|---|---|
| Active material | hADM — human acellular dermal matrix |
| Particle size | Approximately 75 μm |
| Principal components | Collagen, elastin, glycosaminoglycans |
| Source | Donated human skin, processed to remove all cells and DNA |
| Manufacturer | Hans Biomed, South Korea (Korean distribution by Hugel) |
| Delivery | Fine-needle multi-point injection into the dermis |
| Appointment | About 30–40 minutes including topical anaesthetic |
| Targets | Dermal density, texture, hydration — particularly in thin skin |
| Does not treat | Volume loss, contour laxity, deep dynamic wrinkles |
What smaller particles actually change
In this class, particle size is not a specification detail. It determines where the product can be used at all.
Resistance on injection rises with particle size, and two consequences follow. First, more force is needed and the treatment hurts more. Second, product tends to collect rather than distribute. Neither matters much in thick skin. In periorbital skin, both show.
CellREDM addresses this by milling the matrix to approximately 75 μm. Lower injection resistance and less clumping make thin, reactive areas more approachable.
What hADM is — starting with the source
The raw material deserves stating plainly: CellREDM begins with donated human skin. A good deal of promotional material avoids saying so. We would rather you knew and chose.
What is injected is not skin. Donated tissue undergoes decellularisation — detergents, enzymes, repeated freeze-thaw — which removes cells, cellular debris, and the cell-surface antigens and DNA that would otherwise provoke an immune response. What remains is the scaffold: collagen types I and III, elastin, and the glycosaminoglycans that bind water.
This material was not invented for aesthetics. It has a long history in severe burn reconstruction and breast reconstruction, where a surgeon needs a scaffold the body can build into. Products like CellREDM take that same material, reduce it to fine particles, and make it injectable.
Our Re2O reference covers the composition and processing of hADM at greater length.
How we choose between CellREDM and Re2O
Miso Clinic stocks both hADM products. They share a goal, so the choice comes down to site and skin thickness.
Being straightforward about it: no study has compared the two products directly. There is no basis for calling either superior. We stock both because a clinic holding one product ends up using that product everywhere.
| Re2O | CellREDM | |
|---|---|---|
| Manufacturer | L&C Bio | Hans Biomed |
| Particle | Varies by line (a finer line exists separately) | Approximately 75 μm |
| Typically used for | Cheeks, forehead — larger areas | Periorbital and other thin, reactive skin |
| In common | Both are hADM, and both are distributed in Korea as human tissue | |
How this differs from the other classes
Comparison charts tend to list product names. The distinction that matters is simpler: does the product ask the skin to do the work, or does it supply the material?
| HA filler | Collagen stimulator (GOURI, DCLASSY) | PN (Rejuran) | hADM (CellREDM, Re2O) | |
|---|---|---|---|---|
| Mechanism | Occupies space | Foreign-body response | Conditions environment | Supplies matrix directly |
| Primary target | Volume, contour | Laxity, firmness | Texture, fine lines | Dermal density, texture |
| Onset | Immediate | Weeks to months | Weeks | Weeks |
| Adds volume | Yes | Partially | No | No |
Who it suits, and who it does not
Reasonable candidates
- Thin periorbital skin where fine lines and density are the main concern
- Patients who found that other boosters left visible injection points or a lumpy feel
- Skin that feels thin and structurally weak overall
- Skin made reactive by repeated laser or energy-based treatment
- Patients who want to avoid the nodule risk of stimulator-class products
Where CellREDM alone will not get you there
- Hollowing of the cheeks or temples — hADM creates no volume
- A softening jawline — lifting devices or collagen stimulators
- Deep dynamic lines — botulinum toxin or filler
- Pregnancy or breastfeeding, or active infection at the treatment site
- Discomfort with a human-derived material — an entirely reasonable position, and one we can plan around completely
How good is the evidence
Worth setting out plainly.
Acellular dermal matrix as a material has a long record in burn and breast reconstruction, and the principle that removing cells and antigens lowers immune-rejection risk is well established in biomaterials.
However, we found no published clinical trial data specific to CellREDM as a product. Research on injectable hADM generally remains small in scale and short in follow-up. For that reason this page makes no claim about months of duration or a required number of sessions — it is better not to state as settled what has not been settled.
What the appointment involves
The consultation begins by separating density from volume. If hADM is appropriate, site and skin thickness decide which of the two products we use. We always explain the human-derived origin before treatment; if that is not something you are comfortable with, we plan differently.
Topical anaesthetic is applied for 20–30 minutes, then the product is placed into the dermis through a fine needle at many separate points, small volumes closely spaced.
Immediately afterwards each injection point sits slightly raised — product resting in the dermis, which settles as it is absorbed.
Timeline
-
Day 0Redness and raised pointsA response to the injections themselves. The face at this stage is not the result of the treatment.
-
Day 1–3Mostly settledErythema and swelling generally resolve within a few days. Bruising lasts longer.
-
Week 2–4First noticeable changeLess internal tightness, makeup sitting better. The register is "filled in from underneath," not "transformed."
-
Month 2–3Review pointWe assess the actual change here and discuss anything further.
-
BeyondObservationLong-term durability data are limited, so maintenance is decided on what we observe rather than a fixed schedule.
Downtime and aftercare
Most patients return to normal activity the same day. Injection marks may not be fully concealable for a day or two, so allow two or three days before anything important.
- Cleanse gently with lukewarm water on the day; do not rub the treated area
- Avoid sauna, jjimjilbang, strenuous exercise and alcohol for the first day
- Use sun protection diligently
- Resume makeup when your clinician advises
Common questions
It's made from human skin. Is that all right?
CellREDM or Re2O — which is better?
Could my body reject it?
Can it be used around the eyes?
Does it hurt?
How many sessions will I need?
How does this differ from Rejuran?
What does it cost?
About the authoring clinic
This reference was written and reviewed by Dr. Lee Chi-Hak, director of Miso Clinic in Daegu, South Korea. The clinic stocks six collagen boosters and skin boosters with genuinely different active materials — liquid PCL (GOURI), PN (Rejuran), hADM (Re2O, CellREDM) and CaHA (Radiesse, DCLASSY) — and selects between them according to which kind of ageing the face is actually showing. A clinic holding one product will use that product. See our comparison of all six and the references on liquid PCL, polynucleotide, hADM, DCLASSY and Radiesse.
| Director | Dr. Lee Chi-Hak |
|---|---|
| Address | 4F Bombom Building, 125 Dongdeok-ro, Jung-gu, Daegu, South Korea · Exit 1, Kyungpook National University Hospital Station |
| Telephone | +82 53-428-2700 |
| KakaoTalk | Miso Clinic channel |
| Hours | Weekdays 11:00–19:00 (lunch 13:00–14:00) / Saturday 10:00–16:00 (no lunch break) / Closed Sundays and public holidays |
| Website | clinicmiso.co.kr |
| Reference library | Miso Clinic clinical reference library — all six |
| 한국어 | 셀르디엠 진료 자료 (Korean) |
References
- Acellular Dermal Matrix in Reconstructive Surgery: Applications, Benefits, and Cost, Applied Sciences. Composition, decellularisation processing, and established surgical applications.
- CellREDM product information (Hans Biomed). Manufacturer-published composition and particle specification.
- Comparison of Injectable and Sheet-Type Human Acellular Dermal Matrix, Aesthetic Plastic Surgery (2023). Tissue response comparison in an animal model.
- Miso Clinic protocol — formulation selection, injection depth by site, informed-consent procedure.
This page provides general information about an aesthetic treatment and does not substitute for medical diagnosis or care. Outcomes and adverse effects vary with individual skin condition, age and underlying illness, and no result is guaranteed. Decisions about treatment should be made in an in-person consultation with a qualified clinician.